MDACC Study Summary P80-099

Study Summary
No. P80-099:.......Genitourinary; Syndrome......Louise C. Strong......Molecular Genetics

Study Summary Title



Study Summary Number:	P80-099

Study Title:	Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies

Physician

New Patient Referral



Name:	Louise C. Strong	Patients Call:	800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Dept:	Molecular Genetics	Referring MD Call:	800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Phone:	713-792-7555 Contact us about clinical trials

General Information



Disease Group:	Genitourinary Syndrome	Supported By:	N/A

Phase of Study:	N/A	Return Visit:	Blood will be collected during routine visits to MDACC. Field trips may be arranged so that blood from many members of the family may be drawn. There is no reason for any participant to make a special trip back to MDACC.

Treatment Agents:	None	Home Care:	Blood collection packs may be sent to the homes of participants. Blood will be collected and returned to researchers.

Treatment Loc:	Only at MDACC

Estimated Length of Stay in Houston:	None


Description/ Intervention:	The purpose of this clinical research study is to determine · Why some people develop cancers and tumors · Why some families have more cancers than others · Whether certain genes or regions of DNA influence an individual's risk of cancer

Study Objectives / Outcomes

The overall goals are to characterize the genetic events involved in the development of Wilms' tumor, genitourinary anomalies, hemihypertrophy and Beckwith-Wiedemann, and/or aniridia by a combined molecular biology/epidemiologic approach. The study involves investigation of patients with familial and sporadic Wilms' tumor, genitourinary anomalies Beckwith-Wiedemann hemihypertrophy and/or aniridia.

Study Status Information



Study Activation / Registration Date:

IRB Review and Approval Date:	08/27/2002

Study Type:

Recruitment Status:	Open

Projected Accrual:	N/A

Enrollment Eligibility

If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:

1) Patients with familial and sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia, and family members of patients.

Exclusion Criteria:

1) Patients who do not meet inclusion eligilibilty criteria are excluded.

Links

Registration Number: NCT00503893
Study Information on Clinical Trials Registry (clinicaltrials.gov)